{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2022-03-27T23:22:23.362Z","role":"Publisher"},{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10072","date":"2022-03-27T23:22:10.761Z","role":"Approver"}],"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/8944027","type":"dc:BibliographicResource","dc:abstract":"Leber's congenital amaurosis (LCA, MIM 204,000), the earliest and most severe form of inherited retinopathy, accounts for at least 5% of all inherited retinal dystrophies. This autosomal recessive condition is usually recognized at birth or during the first months of life in an infant with total blindness or greatly impaired vision, normal fundus and extinguished electroretinogram (ERG). Nystagmus (pendular type) and characteristic eye poking are frequently observed in the first months of life (digito-ocular sign of Franceschetti). Hypermetropia and keratoconus frequently develop in the course of the disease. The observation by Waardenburg of normal children born to affected parents supports the genetic heterogeneity of LCA. Until now, however, little was known about the pathophysiology of the disease, but LCA is usually regarded as the consequence of either impaired development of photoreceptors or extremely early degeneration of cells that have developed normally. We have recently mapped a gene for LCA to chromosome 17p13.1 (LCA1) by homozygosity mapping in consanguineous families of North African origin and provided evidence of genetic heterogeneity in our sample, as LCA1 accounted for 8/15 LCA families in our series. Here, we report two missense mutations (F589S) and two frameshift mutations (nt 460 del C, nt 693 del C) of the retinal guanylate cyclase (RETGC, GDB symbol GUC2D) gene in four unrelated LCA1 probands of North African ancestry and ascribe LCA1 to an impaired production of cGMP in the retina, with permanent closure of cGMP-gated cation channels.","dc:creator":"Perrault I","dc:date":"1996","dc:title":"Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis."},"evidence":[{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:a998f954-0559-4471-a22f-c23c66ef075a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a998f954-0559-4471-a22f-c23c66ef075a","type":"Proband","allele":{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226054"}},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by Sanger sequencing of PCR products from the GUCY2D locus.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:76d12b78-0dc6-49d4-a13c-5d48e3d7d854_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/10951519","type":"dc:BibliographicResource","dc:abstract":"Leber's congenital amaurosis (LCA) is the earliest and most severe form of all inherited retinal dystrophies responsible for congenital blindness. Genetic heterogeneity of LCA has been suspected since the report by Waardenburg of normal children born to affected parents. In 1995 we localised the first disease causing gene, LCA1, to chromosome 17p13 and confirmed the genetic heterogeneity. In 1996 we ascribed LCA1 to mutations in the photoreceptor-specific guanylate cyclase gene (retGC1). Here, we report on the screening of the whole coding sequence of the retGC1 gene in 118 patients affected with LCA. We found 22 different mutations in 24 unrelated families originating from various countries of the world. It is worth noting that all retGC1 mutations consistently caused congenital cone-rod dystrophy in our series, confirming the previous genotype-phenotype correlations we were able to establish. RetGC1 is an essential protein implicated in the phototransduction cascade, especially in the recovery of the dark state after the excitation process of photoreceptor cells by light stimulation. We postulate that the retGC1 mutations hinder the restoration of the basal level of cGMP of cone and rod photoreceptor cells, leading to a situation equivalent to consistent light exposure during photoreceptor development, explaining the severity of the visual disorder at birth.","dc:creator":"Perrault I","dc:date":"2000","dc:title":"Spectrum of retGC1 mutations in Leber's congenital amaurosis."}},"rdfs:label":"Perrault_1996_Family_9_Proband"},{"id":"cggv:76d12b78-0dc6-49d4-a13c-5d48e3d7d854","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:76d12b78-0dc6-49d4-a13c-5d48e3d7d854_variant_evidence_item"},{"id":"cggv:76d12b78-0dc6-49d4-a13c-5d48e3d7d854_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1."}],"strengthScore":0.5,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":11.05},{"id":"cggv:bea643ba-2528-467b-ac3b-a3a41691ceed_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:bea643ba-2528-467b-ac3b-a3a41691ceed","type":"Proband","allele":{"id":"cggv:c9464ea2-2c5d-4001-868c-59d10a3e8260","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.622del (p.Arg208fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226151"}},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by SSCP and by Sanger sequencing of PCR products from all 20 exons of the GUCY2D locus.","firstTestingMethod":"SSCP","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:2b4151c7-3a44-4c57-b39f-4dbece0fff14_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c9464ea2-2c5d-4001-868c-59d10a3e8260"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519"},"rdfs:label":"Perrault_1996_Family_12_Proband"},{"id":"cggv:2b4151c7-3a44-4c57-b39f-4dbece0fff14","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:2b4151c7-3a44-4c57-b39f-4dbece0fff14_variant_evidence_item"}],"strengthScore":1,"dc:description":"The variant has been down-scored due to the reported consanguinity of the family, which leaves open the possibility that other linked regions of homozygosity may contribute to the phenotype of the patient."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:26eb9070-53de-4450-93ca-8525621d49d1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:26eb9070-53de-4450-93ca-8525621d49d1","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":25,"allele":{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Diagnosis was made soon after birth, but an exact age is not described. Visual acuity was limited to light perception.","phenotypes":["obo:HP_0030532","obo:HP_0003593","obo:HP_0006934","obo:HP_0007843","obo:HP_0000550"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:d0bc7b06-0183-493d-8dc7-4d4930d0e1da_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/16505055","type":"dc:BibliographicResource","dc:abstract":"To test the efficiency of a microarray chip as a diagnostic tool in a cohort of northwestern European patients with Leber congenital amaurosis (LCA) and to perform a genotype-phenotype analysis in patients in whom pathologic mutations were identified.","dc:creator":"Yzer S","dc:date":"2006","dc:title":"Microarray-based mutation detection and phenotypic characterization of patients with Leber congenital amaurosis."}},"rdfs:label":"Yzer_2006_Patient_22597"},{"id":"cggv:d0bc7b06-0183-493d-8dc7-4d4930d0e1da","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d0bc7b06-0183-493d-8dc7-4d4930d0e1da_variant_evidence_item"},{"id":"cggv:d0bc7b06-0183-493d-8dc7-4d4930d0e1da_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1."}],"strengthScore":0.25,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_seg_el","type":"EvidenceLine","specifiedBy":"GeneValiditySegregationEvidencCriteria","strengthScore":1},{"id":"cggv:962f40cc-86fa-4d77-9b9a-101e6972065e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:962f40cc-86fa-4d77-9b9a-101e6972065e","type":"Proband","allele":[{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226075"}},{"id":"cggv:e4fad3d3-36da-46de-9339-fabef65b5cef","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2281C>T (p.Arg761Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/854601"}}],"detectionMethod":"Patient 5 was tested for known LCA-causing variants using an allele-specific method, leading to the detection of 2 variants in GUCY2D.","firstTestingMethod":"Other","phenotypeFreeText":"Refractive error was minimal. Progression of nyctalopia was noticed at 44 years of age. Rod-based ERG was not detectable at age 52.","phenotypes":["obo:HP_0007737","obo:HP_0011463","obo:HP_0000662","obo:HP_0030469","obo:HP_0001133","obo:HP_0000552","obo:HP_0008275","obo:HP_0000539","obo:HP_0008043"],"previousTesting":false,"sex":"Female","variant":[{"id":"cggv:3e9ec7cf-4a98-487d-a693-2c8ac72e5702_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29559409","type":"dc:BibliographicResource","dc:abstract":"GUCY2D has been associated with autosomal recessive Leber congenital amaurosis and autosomal dominant cone-rod dystrophy. This report expands the phenotype of autosomal recessive mutations to congenital night blindness, which may slowly progress to mild retinitis pigmentosa.","dc:creator":"Stunkel ML","dc:date":"2018","dc:title":"Expanded Retinal Disease Spectrum Associated With Autosomal Recessive Mutations in GUCY2D."}},{"id":"cggv:17bf7348-ad38-420a-ac1a-a8d5e20cf161_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e4fad3d3-36da-46de-9339-fabef65b5cef"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409"}],"rdfs:label":"Stunkel_2018_Patient_5"},{"id":"cggv:17bf7348-ad38-420a-ac1a-a8d5e20cf161","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:17bf7348-ad38-420a-ac1a-a8d5e20cf161_variant_evidence_item"}],"strengthScore":0.1,"dc:description":"Evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.2281C>T (p.p.Arg761Trp) variant is limited to computational prediction."},{"id":"cggv:3e9ec7cf-4a98-487d-a693-2c8ac72e5702","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:3e9ec7cf-4a98-487d-a693-2c8ac72e5702_variant_evidence_item"},{"id":"cggv:3e9ec7cf-4a98-487d-a693-2c8ac72e5702_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1."}],"strengthScore":0.25,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f63827f8-f09d-493c-8eeb-b04a210a1fb8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f63827f8-f09d-493c-8eeb-b04a210a1fb8","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":6,"allele":[{"id":"cggv:c301de03-807f-4d2e-8a40-0385c2247396","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.2837C>T (p.Ala946Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226099"}},{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"}],"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from all 20 exons of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","phenotypes":["obo:HP_0000565","obo:HP_0000613","obo:HP_0003593","obo:HP_0012643","obo:HP_0000550","obo:HP_0007703","obo:HP_0000639","obo:HP_0007663","obo:HP_0008043","obo:HP_0000543","obo:HP_0000486","obo:HP_0012426"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"cggv:6b768fbb-02f9-45d1-9ad7-ace608f54498_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c301de03-807f-4d2e-8a40-0385c2247396"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055"},{"id":"cggv:836d1846-0ad2-49d3-bbad-197ed6179f05_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055"}],"rdfs:label":"Yzer_2006_Patient_21067"},{"id":"cggv:6b768fbb-02f9-45d1-9ad7-ace608f54498","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:6b768fbb-02f9-45d1-9ad7-ace608f54498_variant_evidence_item"}],"strengthScore":0.1,"dc:description":"Evidence for the pathogenicity of the NM_000180.4(GUCY2D):c.2837C>T (p.Ala946Val) variant is limited to computational predictions."},{"id":"cggv:836d1846-0ad2-49d3-bbad-197ed6179f05","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:836d1846-0ad2-49d3-bbad-197ed6179f05_variant_evidence_item"},{"id":"cggv:836d1846-0ad2-49d3-bbad-197ed6179f05_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1."}],"strengthScore":0.25,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ec5c1999-1393-4540-936f-5e8fd5b9c801_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ec5c1999-1393-4540-936f-5e8fd5b9c801","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":2,"allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. No perception of light was detected at age 2.5 years. Pupils were wide and minimally responsive to bright light.","phenotypes":["obo:HP_0000543","obo:HP_0030553","obo:HP_0001483","obo:HP_0000550","obo:HP_0002457","obo:HP_0003593","obo:HP_0000639"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:4ac19731-52d8-427f-af09-f6022c94dd98_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055"},"rdfs:label":"Yzer_2006_Patient_22018"},{"id":"cggv:4ac19731-52d8-427f-af09-f6022c94dd98","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:4ac19731-52d8-427f-af09-f6022c94dd98_variant_evidence_item"},{"id":"cggv:4ac19731-52d8-427f-af09-f6022c94dd98_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1."}],"strengthScore":0.25,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a55ae610-e783-48d4-b43d-8238bf063012_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a55ae610-e783-48d4-b43d-8238bf063012","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":3,"allele":[{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19"}],"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exons of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Age was 15 months at time of last evaluation.","phenotypes":["obo:HP_0003593","obo:HP_0000639","obo:HP_0001483","obo:HP_0000662","obo:HP_0000550","obo:HP_0007663"],"previousTesting":true,"previousTestingDescription":"An LCA-specific microarray ChIP was used for initial genotyping, using antisense oligos to screen for 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"cggv:6575113d-3cf1-4fbe-a7d0-8811f28c8de5_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055"},{"id":"cggv:c59d53c2-449b-40d4-9549-6323b8ee56f8_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055"}],"rdfs:label":"Yzer_2006_Patient_441"},{"id":"cggv:c59d53c2-449b-40d4-9549-6323b8ee56f8","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c59d53c2-449b-40d4-9549-6323b8ee56f8_variant_evidence_item"},{"id":"cggv:c59d53c2-449b-40d4-9549-6323b8ee56f8_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1."}],"strengthScore":1,"dc:description":"The variant has been up-scored to reflect the functional evidence of its detrimental effect on GUCY2D activity, as well as its recurrence in multiple affected probands from apparently unrelated families."},{"id":"cggv:6575113d-3cf1-4fbe-a7d0-8811f28c8de5","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:6575113d-3cf1-4fbe-a7d0-8811f28c8de5_variant_evidence_item"},{"id":"cggv:6575113d-3cf1-4fbe-a7d0-8811f28c8de5_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1."}],"strengthScore":0.25,"dc:description":"The variant has been up-scored to reflect the functional evidence of its detrimental effect on GUCY2D activity, as well as its recurrence in multiple affected probands from apparently unrelated families. Up-scoring was limited since the same variant has already been up-scored for recurrence at full strength in a separate proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c7b756e2-47d3-4fa7-b049-4fee703fa083_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c7b756e2-47d3-4fa7-b049-4fee703fa083","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":9,"allele":[{"id":"cggv:2e44d0db-5c1c-4b21-9959-6947f1527564","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.1633C>T (p.Gln545Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/689384"}},{"id":"cggv:f57f359f-d590-4d31-ae88-ec01d3fb3efa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.4(GUCY2D):c.247C>T (p.Arg83Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA397943039"}}],"detectionMethod":"This individual was initially subjected to screening for variants in NYX, CACNA1F, RHO, or TRPM1, with negative results. Whole exome sequencing then detected 2 variants in GUCY2D.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Minor color vision errors were detected by D15 testing.","phenotypes":["obo:HP_0000662","obo:HP_0007987","obo:HP_0003621","obo:HP_0030474","obo:HP_0001133","obo:HP_0002527","obo:HP_0030329"],"previousTesting":true,"previousTestingDescription":"This individual was initially subjected to screening for variants in NYX, CACNA1F, RHO, or TRPM1, with negative results.","secondTestingMethod":"Exome sequencing","sex":"Male","variant":[{"id":"cggv:0eb29583-49d0-4175-915c-02cbffa598ad_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f57f359f-d590-4d31-ae88-ec01d3fb3efa"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409"},{"id":"cggv:24f3a855-c349-4b2d-ab28-d9349058908d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2e44d0db-5c1c-4b21-9959-6947f1527564"},"alleleOrigin":{"id":"obo:GENO_0000877"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29559409"}],"rdfs:label":"Stunkel_2018_Patient_2"},{"id":"cggv:0eb29583-49d0-4175-915c-02cbffa598ad","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:0eb29583-49d0-4175-915c-02cbffa598ad_variant_evidence_item"}],"strengthScore":0.1,"dc:description":"Evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.247C>T (p.Arg83Cys) variant is limited to computational prediction."},{"id":"cggv:24f3a855-c349-4b2d-ab28-d9349058908d","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:24f3a855-c349-4b2d-ab28-d9349058908d_variant_evidence_item"}],"strengthScore":1.5,"dc:description":"NM_000180.4(GUCY2D):c.1633C>T (p.Gln545Ter) is a nonsense variant in exon 7 predicted to trigger NMD or to at least disrupt ~51% of the protein product through truncation."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:04578fdf-5a3b-4281-b644-05261d03fb17_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:04578fdf-5a3b-4281-b644-05261d03fb17","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":23,"allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"detectionMethod":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Retinal pigment epithelium mottling in the mid- and far periphery was minimal.","phenotypes":["obo:HP_0000639","obo:HP_0007814","obo:HP_0007688","obo:HP_0000563","obo:HP_0001483","obo:HP_0008043","obo:HP_0003593","obo:HP_0007663"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:6b4c2d6e-1626-4934-8dae-43c307222226_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055"},"rdfs:label":"Yzer_2006_Patient_20955"},{"id":"cggv:6b4c2d6e-1626-4934-8dae-43c307222226","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:6b4c2d6e-1626-4934-8dae-43c307222226_variant_evidence_item"},{"id":"cggv:6b4c2d6e-1626-4934-8dae-43c307222226_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1."}],"strengthScore":0.25,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:aaef27db-8b83-48b7-ac4e-2fff6d2bbe0a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:aaef27db-8b83-48b7-ac4e-2fff6d2bbe0a","type":"Proband","allele":{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by Sanger sequencing of PCR products from the GUCY2D locus.","firstTestingMethod":"Homozygosity mapping","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:9318b074-c868-411b-bbad-d22338fb7327_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2ae2f86e-7a76-48d6-8120-5cca52c7ae19"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519"},"rdfs:label":"Perrault_1996_Family_11_Proband"},{"id":"cggv:9318b074-c868-411b-bbad-d22338fb7327","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9318b074-c868-411b-bbad-d22338fb7327_variant_evidence_item"},{"id":"cggv:9318b074-c868-411b-bbad-d22338fb7327_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"PMID: 9888789 provides evidence supporting the pathogenicity of the NM_000180.4(GUCY2D):c.1694T>C (p.Phe565Ser) variant by showing that the orthologous bovine F514S point mutation severely decreases the intrinsic cyclase activity of the protein and inactivates one of its calcium-responsive activating switches, CRM1."}],"strengthScore":0.25,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity. Since one such proband has already been up-scored at full strength, this individual has been up-scored at only half strength."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:4d3b2786-a63d-45fd-8696-853140cd5642_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:4d3b2786-a63d-45fd-8696-853140cd5642","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":4,"allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"detectionMethod":" The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK). Subsequent genotyping was performed by Sanger sequencing of PCR products from the relevant exon of the GUCY2D locus.","firstTestingMethod":"Other","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis. Bilateral cataracts were dense and prevented fundoscopy.","phenotypes":["obo:HP_0000639","obo:HP_0030553","obo:HP_0000563","obo:HP_0003593","obo:HP_0007688","obo:HP_0000618","obo:HP_0020049","obo:HP_0000518"],"previousTesting":true,"previousTestingDescription":"The individual was initially screened using an LCA-specific microarray ChIP with antisense oligos to detect 301 known disease-associated variants 6 LCA genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) and two early-onset RP genes (LRAT and MERTK).","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:47d22109-0502-4fd1-a573-0f6de5f1d046_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:545d10d0-e87f-45a0-8ce3-322464c71079"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/16505055"},"rdfs:label":"Yzer_2006_Patient_21557"},{"id":"cggv:47d22109-0502-4fd1-a573-0f6de5f1d046","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:47d22109-0502-4fd1-a573-0f6de5f1d046_variant_evidence_item"},{"id":"cggv:47d22109-0502-4fd1-a573-0f6de5f1d046_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Multiple publications have found functional defects in the NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) variant. PMID: 25477517 shows defective binding to its interacting partner RD3, while PMID: 20050595 and PMID: 23035049 show reduced basal enzymatic activity and inability to interact with the activity-stimulating binding partner GCAP1."}],"strengthScore":0.25,"dc:description":"The variant has been moderately up-scored to reflect its predicted deleterious effect on catalytic activity and its recurrent detection in a homozygous state in affected individuals from multiple families. The up-scoring was limited by the presence of consanguinity, as well as by the same variant having previously been up-scored for recurrence at full strength in another proband."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8a1e99f8-d9be-4c83-9592-4c141e3c9a56_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8a1e99f8-d9be-4c83-9592-4c141e3c9a56","type":"Proband","allele":{"id":"cggv:51b4cc52-9a8b-4e79-a8b3-6e1e9ad2e3d8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000180.3(GUCY2D):c.389del (p.Pro130Leufs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA226143"}},"detectionMethod":"The individual was included in multi-family homozygosity mapping, establishing linkage to chromosome 17p13.1 and particularly between the D17S1353 and D17S1854 markers (PMID: 7581387, PMID: 8641699). Subsequent genotyping was performed by SSCP and by Sanger sequencing of PCR products from all 20 exons of the GUCY2D locus.","firstTestingMethod":"SSCP","phenotypeFreeText":"The individual is described as having Leber congenital amaurosis.","previousTesting":true,"previousTestingDescription":"Linkage mapping of the disease locus to chromosome 17p13.1 (PMID: 7581387, PMID: 8641699)","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:c4758bc3-fcb7-469d-a935-27ae170faba7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:51b4cc52-9a8b-4e79-a8b3-6e1e9ad2e3d8"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/10951519"},"rdfs:label":"Perrault_1996_Family_3_Proband"},{"id":"cggv:c4758bc3-fcb7-469d-a935-27ae170faba7","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:c4758bc3-fcb7-469d-a935-27ae170faba7_variant_evidence_item"}],"strengthScore":1,"dc:description":"The variant has been down-scored due to the reported consanguinity of the family, which leaves open the possibility that other linked genomic regions of homozygosity may contribute to the phenotype."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:019821e5-44ff-4e74-aebe-3bbf738c5a7d","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:62554d53-5ef9-48c9-9d1a-d448518b8872","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Evidence from the Pan-Tissue Plots feature indicates that the expression of GUCY2D at the mRNA level is far higher in adult retina tissue than in any other tissue type with available RNA-seq data found in the database. GUCY2D expression in adult retina is approximately twice that of the second-highest tissue (testis). An alternative database lacking eye data (GTEx, PMID: 23715323) is compatible with this finding in that it shows GUCY2D levels peaking in the testis (https://gtexportal.org/home/gene/GTEX).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30239781","type":"dc:BibliographicResource","dc:abstract":"The human eye is built from several specialized tissues which direct, capture and pre-process information to provide vision. The gene expression of the different eye tissues has been extensively profiled with RNA-seq across numerous studies. Large consortium projects have also used RNA-seq to study gene expression patterning across many different human tissues, minus the eye. There has not been an integrated study of expression patterns from multiple eye tissues compared with other human body tissues. We have collated all publicly available healthy human eye RNA-seq datasets as well as dozens of other tissues. We use this fully integrated dataset to probe the biological processes and pan expression relationships between the cornea, retina, retinal pigment epithelium (RPE)-choroid complex, and the rest of the human tissues with differential expression, clustering and gene ontology term enrichment tools. We also leverage our large collection of retina and RPE-choroid tissues to build the first human weighted gene correlation networks and use them to highlight known biological pathways and eye gene disease enrichment. We also have integrated publicly available single-cell RNA-seq data from mouse retina into our framework for validation and discovery. Finally, we make all these data, analyses and visualizations available via a powerful interactive web application (https://eyeintegration.nei.nih.gov/).","dc:creator":"Bryan JM","dc:date":"2018","dc:title":"Identifying core biological processes distinguishing human eye tissues with precise systems-level gene expression analyses and weighted correlation networks."},"rdfs:label":"GUCY2D mRNA is highly expressed in human retina"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1,"dc:description":"The high level of specificity of GUCY2D mRNA expression to the retina (at twice the level of the closest non-retinal tissue) has been used as a rationale to up-score this data from 0.5 to 1 point."},{"id":"cggv:fd381d1c-b207-49dd-a99c-99f3148317d8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:8a276cb2-13aa-45d1-90e3-907d1b866f22","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"Mouse Rd3 was immunoprecipitated by monoclonal antibody and co-purifying proteins were identified by LC-MS/MS. The highest-scoring interacting partner was Gucy2e, the mouse ortholog of GUCY2D (Table S1). This was confirmed by western blotting (Figure 2A) and found to be dependent on the C-terminus of Gucy2e (Figure 5).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21078983","type":"dc:BibliographicResource","dc:abstract":"Guanylate cyclases, GC1 and GC2, are localized in the light-sensitive outer segment compartment of photoreceptor cells, where they play a crucial role in phototransduction by catalyzing the synthesis of cGMP, the second messenger of phototransduction, and regulating intracellular Ca(2+) levels in combination with the cGMP-gated channel. Mutations in GC1 are known to cause Leber congenital amaurosis type 1 (LCA1), a childhood disease associated with severe vision loss. Although the enzymatic and regulatory properties of guanylate cyclases have been studied extensively, the molecular determinants responsible for their trafficking in photoreceptors remain unknown. Here we show that RD3, a protein of unknown function encoded by a gene associated with photoreceptor degeneration in humans with Leber congenital amaurosis type 12 (LCA12), the rd3 mouse, and rcd2 collie, colocalizes and interacts with GC1 and GC2 in rod and cone photoreceptor cells of normal mice. GC1 and GC2 are undetectable in photoreceptors of the rd3 mouse deficient in RD3 by immunofluorescence microscopy. Cell expression studies show that RD3 mediates the export of GC1 from the endoplasmic reticulum to endosomal vesicles, and that the C terminus of GC1 is required for RD3 binding. Our results indicate that photoreceptor degeneration in the rd3 mouse, rcd2 dog, and LCA12 patients is caused by impaired RD3-mediated guanylate cyclase expression and trafficking. The resulting deficiency in cGMP synthesis and the constitutive closure of cGMP-gated channels might cause a reduction in intracellular Ca(2+) to a level below that required for long-term photoreceptor cell survival.","dc:creator":"Azadi S","dc:date":"2010","dc:title":"RD3, the protein associated with Leber congenital amaurosis type 12, is required for guanylate cyclase trafficking in photoreceptor cells."},"rdfs:label":"GUCY2D protein-protein interaction with RD3"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5,"dc:description":"This study demonstrates a physical interaction between the mouse orthologs of GUCY2D (cause of LCA1) and RD3 (cause of LCA12) and the requirement for this interaction for proper GUCY2D localization."},{"id":"cggv:10a9a630-379b-4ceb-810a-e25863524553","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:3f3e1656-fad5-45ae-8bf6-234be483b549","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"The ability of the exogenously expressed enzyme to efficiently catalyze cGMP production is consistent with the loss of photoreceptor function that is characteristic of the disease, as abnormalities in cGMP levels have long been associated with photoreceptor degeneration (PMID: 4369896).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/1356371","type":"dc:BibliographicResource","dc:abstract":"We have isolated and characterized cDNA clones encoding the human retinal guanylyl cyclase (retGC), a novel member of the membrane guanylyl cyclase gene family. Like other membrane guanylyl cyclases, the 1101 aa retGC is predicted to have a hydrophobic amino-terminal signal sequence followed by a large extracellular domain, a single membrane spanning domain, a kinase homology domain, and a guanylyl cyclase catalytic domain. In contrast to other membrane guanylyl cyclases, such as natriuretic peptide receptors, retGC has a relatively high basal level of activity when expressed in human 293 cells. cGMP production by retGC is unaffected by any of the known natriuretic peptides. In situ hybridization analysis of a variety of rhesus monkey tissues showed retGC transcripts to be localized exclusively along the retinal outer nuclear layer, corresponding to the nuclei of the rod and cone photoreceptor cells. Our results suggest that retGC may synthesize cGMP required for recovery of the dark state after phototransduction.","dc:creator":"Shyjan AW","dc:date":"1992","dc:title":"Molecular cloning of a retina-specific membrane guanylyl cyclase."},"rdfs:label":"GUCY2D produces cGMP as a receptor guanylyl cyclase"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5,"dc:description":"The ability of GUCY2D to catalyze cGMP production is consistent with the loss of photoreceptor function in patients and the known association between abnormalities in cGMP levels and photoreceptor degeneration."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:686caad7-c84a-4c5e-b8f2-588ed6ecdd69","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f2adf4bc-b57f-40fd-9c4b-738cb9314a6f","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"Treatment with the human GUCY2D gene restored proper localization of alpha-transducin (Figs. 3a-3b), which was first reported by PMID: 15623748 to be abnormal in this model. Treatment corrected the defect in scotopic b-wave amplitude by 65-100% (Figs. 4a-4b). Cone amplitude was corrected from 20% of wild-type to 65% of wild-type (Fig. 4c). Similar results were obtained with the mouse Gucy2e transgene (Fig. 5). Head-tracking behavior (measure of visual acuity and contrast sensitivity) was fully corrected by treatment (Fig. 6). Moderate cone preservation was also demonstrated by normalization of alpha-transducin staining, showing a 20% increase in cone numbers relative to the untreated control (Fig. 7r).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21671801","type":"dc:BibliographicResource","dc:abstract":"Leber congenital amaurosis (LCA) is a severe retinal dystrophy manifesting from early infancy as poor vision or blindness. Loss-of-function mutations in GUCY2D cause LCA1 and are one of the most common causes of LCA, accounting for 20% of all cases. Human GUCY2D and mouse Gucy2e genes encode guanylate cyclase-1 (GC1), which is responsible for restoring the dark state in photoreceptors after light exposure. The Gucy2e(-/-) mouse shows partially diminished rod function, but an absence of cone function before degeneration. Although the cones appear morphologically normal, they exhibit mislocalization of proteins involved in phototransduction. In this study we tested the efficacy of an rAAV2/8 vector containing the human rhodopsin kinase promoter and the human GUCY2D gene. Following subretinal delivery of the vector in Gucy2e(-/-) mice, GC1 protein was detected in the rod and cone outer segments, and in transduced areas of retina cone transducin was appropriately localized to cone outer segments. Moreover, we observed a dose-dependent restoration of rod and cone function and an improvement in visual behavior of the treated mice. Most importantly, cone preservation was observed in transduced areas up to 6 months post injection. To date, this is the most effective rescue of the Gucy2e(-/-) mouse model of LCA and we propose that a vector, similar to the one used in this study, could be suitable for use in a clinical trial of gene therapy for LCA1.","dc:creator":"Mihelec M","dc:date":"2011","dc:title":"Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of leber congenital amaurosis caused by guanylate cyclase-1 deficiency."},"rdfs:label":"Rescue of mouse Gucy2e homozygous knockout by AAV-GUCY2D"}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":1.5,"dc:description":"Injection of the AAV-borne transgene at least partially rescues all phenotypes of interest, whether the transgene is mouse Gucy2e or human GUCY2D. Scoring has been kept at the moderate level due to the potential for overexpression effects, the design of the experiment in mice rather than in human patients, and the absence of a patient-derived variant."},{"id":"cggv:3a4797d7-3fbd-4bcd-b9e4-5ed50c6bf41f","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:5a7f828a-eb9f-401e-b263-c57b51fad09b","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"The model system recapitulates the functional (ERG) defects of the human patients, particularly in the cone and to a lesser extent in the rod photoreceptor cells. The absence of more severe rod defects is explained by a mouse-specific expression pattern of a gene paralog. Mice and humans with loss-of-function both exhibit some defects in retinal morphology as well. By 5 weeks of age, Gucy2e-deficient animals exhibit dramatic reduction/degeneration of cones in the outer nuclear layer (Fig. 3ad). This was confirmed by disappearance of labeling of cone cell nuclei by the lectin PNA (Fig. 3g-h). ERG showed that rod a-wave and b-wave were markedly reduced by 1 month of age, while cone responses were nondetectable as early as 2 months of age (Fig. 4a-b). A proposed explanation for the absence of more severe rod defects is the continued presence of the Gucy2f paralog in this mouse model, which may compensate for the absence of Gucy2e function in rod cells specifically. This hypothesis has been confirmed in a subsequent double-knockout model (PMID: 17255100)","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/10407028","type":"dc:BibliographicResource","dc:abstract":"One of two orphan photoreceptor guanylyl cyclases that are highly conserved from fish to mammals, GC-E (or retGC1) was eliminated by gene disruption. Expression of the second retinal cyclase (GC-F) as well as the numbers and morphology of rods remained unchanged in GC-E null mice. However, rods isolated from such mice, despite having a normal dark current, recovered from a light flash markedly faster. Unexpectedly, the a- and b-waves of electroretinograms (ERG) from dark-adapted null mice were suppressed markedly. Cones, initially present in normal numbers in the retina, disappeared by 5 weeks, based on ERG and histology. Thus, the GC-E-deficient mouse defines a model for cone dystrophy, but it also demonstrates that morphologically normal rods display paradoxical behavior in their responses to light.","dc:creator":"Yang RB","dc:date":"1999","dc:title":"Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior."},"rdfs:label":"Phenotypes of a homozygous Gucy2e mouse knockout model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1.5,"dc:description":"The mouse model recapitulates the key visual defects of the human patients. Despite the relative sparing of rod function, this has only been moderately down-scored due to evidence that these photoreceptor cells in the mouse rely on a gene paralog instead."},{"id":"cggv:df90bc7e-ff22-4230-824f-b3f96b3ee962","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:5a0154aa-cea7-4937-ab0b-60361e597eb8","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"This publication confirms previously-reported ERG abnormalities of rod and especially cone photoreceptors (PMID: 10407028). The abnormal retinal morphology HPO term refers to abnormalities in the ultrastructure of the photoreceptor outer segment, which exhibited disorganization (Figures S2B, S2F, 8C, and 8E) and low GCAP1 and GCAP2 expression levels (Figures 5J and 5N), providing early signs of instability and degeneration.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17255100","type":"dc:BibliographicResource","dc:abstract":"Retinal guanylate cyclases 1 and 2 (GC1 and GC2) are responsible for synthesis of cyclic GMP in rods and cones, but their individual contributions to phototransduction are unknown. We report here that the deletion of both GC1 and GC2 rendered rod and cone photoreceptors nonfunctional and unstable. In the rod outer segments of GC double knock-out mice, guanylate cyclase-activating proteins 1 and 2, and cyclic GMP phosphodiesterase were undetectable, although rhodopsin and transducin alpha-subunit were mostly unaffected. Outer segment membranes of GC1-/- and GC double knock-out cones were destabilized and devoid of cone transducin (alpha- and gamma-subunits), cone phosphodiesterase, and G protein-coupled receptor kinase 1, whereas cone pigments were present at reduced levels. Real time reverse transcription-PCR analyses demonstrated normal RNA transcript levels for the down-regulated proteins, indicating that down-regulation is posttranslational. We interpret these results to demonstrate an intrinsic requirement of GCs for stability and/or transport of a set of membrane-associated phototransduction proteins.","dc:creator":"Baehr W","dc:date":"2007","dc:title":"The function of guanylate cyclase 1 and guanylate cyclase 2 in rod and cone photoreceptors."},"rdfs:label":"Updated phenotypes from homozygous Gucy2e knockout mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0,"dc:description":"While this paper adds phenotypic detail to an existing mouse model, scoring for this mouse has been performed for PMID: 10407028 instead."},{"id":"cggv:3d0c2d5d-9d4a-4cd6-aa71-d6b46146906b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:b7f47b04-9778-4ddb-a744-11b2acd5d2d4","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Chickens harboring the null variant in a homozygous state have dramatically lower levels of cGMP in the retina (Figure 1) and absent expression of GC1, the GUCY2D ortholog (Figure 2). Rod and cone photoreceptor cells develop normally, but have little to no function according to ERG. This is similar to the normal fundus appearance in LCA patients, despite severe early vision loss. A related article on the same model (PMID: 16700630) establishes that the chickens harboring the null allele are also similar to human patients in that they exhibit early onset blindness and abnormal optokinetic reflex scores (a surrogate for nystagmus). The model also recapitulates the mechanism (biallelic GUCY2D loss-of-function) and mode of inheritance (homozygous state) of the human patients.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/9448321","type":"dc:BibliographicResource","dc:abstract":"The retinas of the retinal degeneration (rd) chicken are fully developed and possess normal morphology at hatching but fail to respond to light stimulation. Analyses of retinal cGMP, the internal messenger of phototransduction, show that the amount of cGMP in predegenerate, fully developed rd/rd photoreceptors is 5-10 times less than that seen in normal photoreceptor cells. We show that the low levels of cGMP in rd chicken retina are a consequence of a null mutation in the photoreceptor guanylate cyclase (GC1) gene. Thus, the rd chicken is a model for human Leber's congenital amaurosis. Absence of GC1 in rd retina prevents phototransduction and affects survival of rods and cones but does not interfere with normal photoreceptor development.","dc:creator":"Semple-Rowland SL","dc:date":"1998","dc:title":"A null mutation in the photoreceptor guanylate cyclase gene causes the retinal degeneration chicken phenotype."},"rdfs:label":"Homozygous disruption of the chicken ortholog of GUCY2D"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2,"dc:description":"This model was not scored at a higher level due to the natural occurrence of the variant (necessitating an inbred background that may have other linked areas of homozygosity affecting disease severity)."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":4099,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"cggv:1b1e968c-59b9-4ae7-8f5c-6d15328a4312","type":"GeneValidityProposition","disease":"obo:MONDO_0100453","gene":"hgnc:4689","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"The *GUCY2D* gene was first reported in relation to autosomal recessive cases of Leber congenital amaurosis in 1996 (Perrault et al., PMID: 8944027). Affected individuals have since been identified in a number of other publications (PMID: 16505055, PMID: 29559409, PMID: 23035049), with causal biallelic variants in *GUCY2D* specifically diagnostic for either Leber congenital amaurosis 1 (more severe) or congenital stationary night blindness type 1I (milder and later onset). Both disease entities are completely penetrant, however, patients diagnosed with Leber congenital amaurosis 1 present with severe visual impairment before the age of 5 (usually during the first year of life) while their counterparts with congenital stationary night blindness type 1I are diagnosed between the ages of 9 and 45, presenting with night blindness since childhood and gradual progression to mild retinal dystrophy (PMID: 29559409). Patients with Leber congenital amaurosis 1 also exhibit other eye-specific features, including nystagmus, photophobia, strabismus, eye poking, keratoconus, attenuation of retinal blood vessels, optic disc pallor, and mild retinal pigment epithelium mottling, often with a relatively normal appearance to the fundus. Patients with congenital stationary night blindness type 1I exhibit only a subset of these features, including attenuation of retinal blood vessels and progressive visual field constriction. Electroretinogram (ERG) response is nondetectable in Leber congenital amaurosis 1 patients, however, those with congenital stationary night blindness type 1I initially exhibit nondetectable responses only in rod-based ERG, while cone-based ERG responses may remain normal until the third decade of life or later. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found the molecular mechanism (biallelic loss of function in the GUCY2D gene product) and mode of inheritance (autosomal recessive) to be consistent among unrelated patients diagnosed with either Leber congenital amaurosis 1 or congenital stationary night blindness type 1I, while the phenotypic variability between them appeared to represent a spectrum of disease rather than separate disease entities. Therefore, cases of Leber congenital amaurosis 1 or congenital stationary night blindness type 1I have been lumped into a single disease entity, referred to as *GUCY2D*-related recessive retinopathy (MONDO:0100453). Two additional disease entities, cone-rod dystrophy 6 and central areolar choroidal dystrophy 1, were asserted in relation to monoallelic variants in *GUCY2D*, particularly those located in the dimerization domain (PMID: 11115851, PMID: 11709018, PMID: 29061346). While these disease entities are characterized by similar phenotypes, their different mode of inheritance and unique variants suggested a different mechanism of pathogenesis. Thus, *GUCY2D* was separately curated for its relationship to this disease entity, referred to as *GUCY2D*-related dominant retinopathy (MONDO:0100441).\n\nEight suspected pathogenic variants were scored as part of this curation (two nonsense, one frameshift, and five missense), which have been collectively reported in twelve probands in three publications (PMID: 8944027, PMID: 16505055, PMID: 29559409). Eight probands were homozygous for their respective variants (PMID: 8944027, PMID: 16505055), and five were reported to have consanguineous parents (PMID: 8944027, PMID: 16505055). The four other probands were compound heterozygotes within the *GUCY2D* locus (PMID: 16505055, PMID: 29559409). Two families with segregation evidence were available in these publications (PMID: 8944027), and contributed to the scoring of the gene-disease relationship. More case-level data was available (PMID: 23035049, PMID: 29559409), but was not scored as part of this curation as the maximum scoring for this evidence type had already been reached.\n\nThis gene-disease relationship has not been studied in case-control studies at the single variant level or aggregate variant level.\n\nThe mechanism of pathogenicity appears to be biallelic loss of function, characterized in some cases by frameshift or nonsense variants predicted to trigger a decrease in the amount of the gene product (PMID: 8944027, PMID: 29559409). All probands found for this curation harbored two variant alleles within the *GUCY2D* locus.\n\nThis gene-disease association is also supported by experimental evidence that *GUCY2D* expression is dramatically higher in the retina relative to control tissues (PMID: 30239781), particularly along the retinal outer nuclear layer (PMID: 1356371). Proper subcellular localization of GUCY2D protein requires its C-terminus to physically interact with the RD3 protein, which is encoded by a gene that harbors causal variants for Leber congenital amaurosis 12 (PMID: 21078983). Biochemical studies have demonstrated that *GUCY2D* encodes a receptor guanylyl cyclase that catalyzes cGMP production as part of the recovery of the dark state following visual excitation (PMID: 1356371). This helps explain why chickens homozygous for a null variant of the *GUCY2D* ortholog exhibit dramatically reduced cGMP levels within the retina, nondetectable ERG responses from rod and cone photoreceptors, early onset blindness, and optokinetic reflex abnormalities analogous to nystagmus (PMID: 9448321). Similarly, mice with homozygous knockout of *Gucy2e* (the murine *GUCY2D* ortholog) exhibit degeneration and loss of cone photoreceptor cells in the outer nuclear layer, nondetectable cone-based ERG responses, reduced amplitude of rod-based ERG responses, and loss of visual acuity (PMID: 10407028, PMID: 17255100, PMID: 21671801). Rod photoreceptor function has been shown to be relatively preserved in these mice due to their dependence on a gene paralog (PMID: 17255100). These mouse phenotypes can be partially rescued by injection of adeno-associated virus (AAV) delivering wild-type human *GUCY2D* or mouse *Gucy2e*.\n\nIn summary, *GUCY2D* is definitively associated with *GUCY2D*-related recessive retinopathy. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a definitive classification.","dc:isVersionOf":{"id":"cggv:dcb8350d-c57f-43e3-9e9f-d059ebbf61c9"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}